Award NoticeActiveSPE2D222R0117
Olopatadine HCL 0.1% Ophthalmic Solution
DEPT OF DEFENSE / DEFENSE LOGISTICS AGENCY / DLA TROOP SUPPORTKey dates?
- Posted?
- May 4, 2026
- Response deadline?
- —
- Archive date?
- —
- Archive type?
- autocustom
Classification?
- Notice type?
- Award Notice
- Base type?
- Award Notice
- Set-aside?
- —
- Set-aside code?
- —
- PSC?
- 6505
NAICS?
Issuing office?
- Department?
- DEPT OF DEFENSE
- Sub-tier?
- DEFENSE LOGISTICS AGENCY
- Office?
- DLA TROOP SUPPORT
- Office code?
- 097.97AS.DLA TRP SUPT MED.SPE2D2
- Organization type?
- OFFICE
- Office address?
- PHILADELPHIA, PA, 19111, USA
Place of performance?
- Street?
- —
- Street 2?
- —
- City?
- Ontario
- State?
- Canada
- Zip?
- —
- Country?
- CANADA
Contacts?
- Kyle Lewickiprimary
- Jason Wraysecondary
Description?
Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle. Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23. Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027. Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003. Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026. Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract. Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025. Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract. Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract. Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023. Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Attachments (11)?
- Download📎 Modification+P00005+SPE2D223D0007.PDFapplication/pdf · 188 KB
- Download📎 Option+Year+2+Modification+P00006+SPE2D223D0007.PDFapplication/pdf · 25 KB
- Download📎 Modification+P00008+SPE2D223D0007+Option+Year+3.PDFapplication/pdf · 25 KB
- Download📎 Option+Year+1+Modification+P00004+SPE2D2-23-D-0007.PDFapplication/pdf · 25 KB
- Download📎 Modification+P00007+SPE2D223D0007.PDFapplication/pdf · 197 KB
- Download📎 Signed+Olopatadine+HCL+Oph+Sol+SPE2D223D0007+P00011+Mfg+NDC+Change.pdfapplication/pdf · 237 KB
- Download📎 SF30_SPE2D223D0007P00002.PDFapplication/pdf · 173 KB
- Download📎 Modification+P00010+SPE2D223D0007.PDFapplication/pdf · 171 KB
- Download📎 Signed+Award+SPE2D2-23-D-0007+Olopatadine+HCL+0.1%25+Ophthalmic+Solution.pdfapplication/pdf · 807 KB
- Download📎 Signed+SPE2D223D0007+P00003.pdfapplication/pdf · 867 KB
- Download📎 Signed+Modification+P00001+SPE2D2-23-D-0007.pdfapplication/pdf · 109 KB
Award?
- Number?
- SPE2D223D0007
- Amount?
- $17,621,453.20
- Date?
- —
- UEI?
- GQLDJJ8AQNN5
- Awardee address?
- Camarillo, California, 93012, UNITED STATES
Other notices in this solicitation?
- Award NoticeOlopatadine HCL 0.1% Ophthalmic SolutionJan 27, 2026LATEST
- Award NoticeOlopatadine HCL 0.1% Ophthalmic SolutionJan 21, 2025
- Award NoticeOlopatadine HCL 0.1% Ophthalmic SolutionJan 26, 2024
- Award NoticeOlopatadine HCL 0.1% Ophthalmic SolutionAug 24, 2023
- Award NoticeOlopatadine HCL 0.1% Ophthalmic SolutionFeb 22, 2023
- Award NoticeOlopatadine HCL 0.1% Ophthalmic SolutionFeb 15, 2023
- SolicitationOlopatadine HCL 0.1% Ophthalmic SolutionJun 21, 2022
- PresolicitationOlopatadine HCL 0.1% Ophthalmic SolutionJun 3, 2022
Similar open contracts
Metadata?
- Notice ID?
- bbf974a01ba842b69164b07632c5377e
- Full path?
- DEPT OF DEFENSE.DEFENSE LOGISTICS AGENCY.DLA TROOP SUPPORT
- Office code?
- 097.97AS.DLA TRP SUPT MED.SPE2D2
- Ingested?
- May 5, 2026
- Updated?
- Jul 26, 2026